0001140361-16-087737.txt : 20161123
0001140361-16-087737.hdr.sgml : 20161123
20161123133503
ACCESSION NUMBER: 0001140361-16-087737
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161121
FILED AS OF DATE: 20161123
DATE AS OF CHANGE: 20161123
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200915291
FISCAL YEAR END: 0430
BUSINESS ADDRESS:
STREET 1: BUILDING 227, TETRICUS SCIENCE PARK
STREET 2: PORTON DOWN
CITY: SALISBURY, WILTSHIRE
STATE: X0
ZIP: SP4 0JQ
BUSINESS PHONE: 44 0 1980 753002
MAIL ADDRESS:
STREET 1: BUILDING 227, TETRICUS SCIENCE PARK
STREET 2: PORTON DOWN
CITY: SALISBURY, WILTSHIRE
STATE: X0
ZIP: SP4 0JQ
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Therapeutics, Inc.
DATE OF NAME CHANGE: 20140916
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery, Inc
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery Inc
DATE OF NAME CHANGE: 20060105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Renzi David
CENTRAL INDEX KEY: 0001631294
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36830
FILM NUMBER: 162015923
MAIL ADDRESS:
STREET 1: C/O CARBYLAN THERAPEUTICS, INC.
STREET 2: 3181 PORTER DRIVE
CITY: PALO ALTO
STATE: CA
ZIP: 94304
4
1
doc1.xml
FORM 4
X0306
4
2016-11-21
1
0001348911
KalVista Pharmaceuticals, Inc.
CBYL
0001631294
Renzi David
C/O CARBYLAN THERAPEUTICS, INC.
39899 BALENTINE DRIVE, SUITE 200
NEWARK
CA
94560
1
1
0
0
President & CEO
Common Stock
2016-11-21
4
M
0
36640
7.84
A
36640
D
Common Stock
2016-11-21
4
F
0
33454
8.5932
D
3186
D
Common Stock
2016-11-21
4
U
0
3186
8.5932
D
0
D
Stock Option (Right to Buy)
7.84
2016-11-21
4
M
0
36640
0.00
D
2023-06-06
Common Stock
36640
0
D
The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction.
The option is fully vested and exercisable.
/s/ David Renzi
2016-11-23